Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Markus Cornberg

Showing results (211-220 of 350) with videos related to

Pageof 35
Sort By:
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|February 25, 2016
Applicability of Hepatitis C Virus RNA Viral Load Thresholds for 8-Week Treatments in Patients With Chronic Hepatitis C Virus Genotype 1 InfectionJohannes Vermehren, Benjamin Maasoumy, Raoel Maan, et al.
Journal of Hepatology|July 22, 2022
Impact of COVID-19 on the liver and on the care of patients with chronic liver disease, hepatobiliary cancer, and liver transplantation: An updated EASL position paperThomas Marjot, Christiane S Eberhardt, Tobias Boettler, et al.
Journal of Immunology (Baltimore, Md. : 1950)|February 19, 2010
CD8 T cell cross-reactivity networks mediate heterologous immunity in human EBV and murine vaccinia virus infectionsMarkus Cornberg, Shalyn C Clute, Levi B Watkin, et al.
The Journal of Clinical Investigation|April 15, 2006
Narrowed TCR repertoire and viral escape as a consequence of heterologous immunityMarkus Cornberg, Alex T Chen, Lee A Wilkinson, et al.
Hepatology (Baltimore, Md.)|October 19, 2011
Hepatitis E virus (HEV)-specific T-cell responses are associated with control of HEV infectionPothakamuri Venkata Suneetha, Sven Pischke, Verena Schlaphoff, et al.
Plos One|April 23, 2014
PEG-IFN alpha but not ribavirin alters NK cell phenotype and function in patients with chronic hepatitis CAntoaneta A Markova, Ulrike Mihm, Verena Schlaphoff, et al.
Frontiers in Immunology|September 26, 2019
Hepatitis E Virus (HEV)-Specific T Cell Receptor Cross-Recognition: Implications for ImmunotherapyChai Fen Soon, Shihong Zhang, Pothakamuri Venkata Suneetha, et al.
Frontiers in Immunology|October 20, 2017
Interpreting T-Cell Cross-reactivity through Structure: Implications for TCR-Based Cancer ImmunotherapyDinler A Antunes, Maurício M Rigo, Martiela V Freitas, et al.
Journal of Hepatology|June 17, 2017
Origin, prevalence and response to therapy of hepatitis C virus genotype 2k/1b chimerasSimone Susser, Julia Dietz, Bernhard Schlevogt, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|June 9, 2026
Acute HEV Infection Is a Relevant Cause of Decompensation and ACLF in Patients With Liver CirrhosisKatja Dinkelborg, Christian Niehaus, Birgit Bremer, et al.
Pageof 35

Showing results (211-220 of 350) with videos related to

Sort By:
Pageof 35
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|February 25, 2016
Applicability of Hepatitis C Virus RNA Viral Load Thresholds for 8-Week Treatments in Patients With Chronic Hepatitis C Virus Genotype 1 InfectionJohannes Vermehren, Benjamin Maasoumy, Raoel Maan, et al.
Journal of Hepatology|July 22, 2022
Impact of COVID-19 on the liver and on the care of patients with chronic liver disease, hepatobiliary cancer, and liver transplantation: An updated EASL position paperThomas Marjot, Christiane S Eberhardt, Tobias Boettler, et al.
Journal of Immunology (Baltimore, Md. : 1950)|February 19, 2010
CD8 T cell cross-reactivity networks mediate heterologous immunity in human EBV and murine vaccinia virus infectionsMarkus Cornberg, Shalyn C Clute, Levi B Watkin, et al.
The Journal of Clinical Investigation|April 15, 2006
Narrowed TCR repertoire and viral escape as a consequence of heterologous immunityMarkus Cornberg, Alex T Chen, Lee A Wilkinson, et al.
Hepatology (Baltimore, Md.)|October 19, 2011
Hepatitis E virus (HEV)-specific T-cell responses are associated with control of HEV infectionPothakamuri Venkata Suneetha, Sven Pischke, Verena Schlaphoff, et al.
Plos One|April 23, 2014
PEG-IFN alpha but not ribavirin alters NK cell phenotype and function in patients with chronic hepatitis CAntoaneta A Markova, Ulrike Mihm, Verena Schlaphoff, et al.
Frontiers in Immunology|September 26, 2019
Hepatitis E Virus (HEV)-Specific T Cell Receptor Cross-Recognition: Implications for ImmunotherapyChai Fen Soon, Shihong Zhang, Pothakamuri Venkata Suneetha, et al.
Frontiers in Immunology|October 20, 2017
Interpreting T-Cell Cross-reactivity through Structure: Implications for TCR-Based Cancer ImmunotherapyDinler A Antunes, Maurício M Rigo, Martiela V Freitas, et al.
Journal of Hepatology|June 17, 2017
Origin, prevalence and response to therapy of hepatitis C virus genotype 2k/1b chimerasSimone Susser, Julia Dietz, Bernhard Schlevogt, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|June 9, 2026
Acute HEV Infection Is a Relevant Cause of Decompensation and ACLF in Patients With Liver CirrhosisKatja Dinkelborg, Christian Niehaus, Birgit Bremer, et al.
Pageof 35